Neonatal sepsis in Peshawar: Author’s reply

I am responding to the letter of Ali et al.1

(1) The total number of babies (1003) in our article represents the number of cases after removal of patients meeting the exclusion criteria. We did find isolated cases of Streptococcus sp, Salmonella, and Enterococci, but they happened to fall in the excluded group.

These organisms accounted for < 0.5% of the spectrum as a whole. This is similar to the findings of Maryam et al.2 in a public sector institution with a population of similar socioeconomic, cultural, religious, and climatic background. Their study was carried out in the same time period as ours but completely independently and blinded from ours. In their series of 284 cases, they grew Escherichia coli (130 cases; 45.7%), Klebsiella (49 cases; 17.2%), Pseudomonas (46 cases; 16.2%), Staphylococcus aureus (39 cases; 13.7%), Staphylococcus epidermidis (18 cases; 6.34%), Streptococcus sp (1 case; 0.3%), and Salmonella (1 case; 0.3%).

The numbers are slightly different among the studies from south of Pakistan.3 This is not surprising as neonatal sepsis is known for the temporal and regional variation of the spectrum of its organisms even in different hospitals within the same city.

(2) The basic message from the majority of studies from Pakistan is the same: Gram negative organisms are the main cause of neonatal sepsis in Pakistan, followed by S. aureus. This group of organisms is responsible for > 99% of the spectrum, and unfortunately the grave situation of multidrug resistance is emerging among these organisms. That is where research needs to be concentrated instead of on the organisms responsible for < 0.5% of the spectrum (Salmonella, Streptococcus sp, etc), which do not carry any significance for overall neonatal mortality and morbidity.

(3) Out of 296 cases of S. aureus in our series, ampicillin was tested on 285 cases, with 171 (60%) sensitive to it, and 279 were tested with augmentin, with 75 (26.9%) sensitive to it. I agree with Ali et al. that this pattern of sensitivity looks unusual as far as S. aureus is concerned, although this phenomenon is known to occur with β-lactamase-producing E. coli. It may be due to the various strengths of augmentin discs available, the known biochemical instability of clavulanic acid, or the difficulty of interpretation when a combination of two antibiotics is used in one disc using the disc diffusion technique. However, I would be interested to hear more expert opinion on this. Our series did not exclude hospital acquired infections.

(4) The longitudinal analysis of our data shows an increasing sensitivity to penicillin and decreasing sensitivity to cephalosporins, particularly cefotaxime, over the last half decade. This is consistent with the change in antibiotic use in Pakistan since the early 1990s when penicillin/gentamicin was replaced by cephalosporins/amikacin as the first line antibiotic treatment. Most of the Gram negative organisms in Pakistan maintain a very high degree of sensitivity to amikacin4 but not to gentamicin. I feel that penicillin/amikacin may be a very good choice as the first line antibiotic in neonatal units in Pakistan. It is high time that we reviewed our antibiotic policies and at the same time approach the government to rationalise antibiotic marketing in this country.

S Rahman
St Mary’s Hospital, Praed Street, London W2 1NY, UK; sajjadjan@hotmail.com

References

Serum S-100 protein does not correlate with cerebral ultrasound scans in preterm infants

Whitelaw et al.5 recently reported that S-100 protein concentration was 20–200 times higher than control levels in the cerebrospinal fluid of infants with posthaemorrhagic ventricular dilatation. S-100 protein is produced only within the brain by astrocytes, but it can be detected in the serum after cerebral damage in adults with stroke, where it is a marker of infarction volume,6 and it has also been found to be useful in head injury.7 A study of term infants found that serum S-100 protein levels were detectable after uncomplicated delivery.8 Cerebrospinal fluid is not often taken from preterm infants, and an easily obtainable serum marker for brain cell damage would be of considerable interest.

The aims of our study were to determine firstly whether S-100 protein could be measured in the serum of preterm infants during the first week after birth. Thirty preterm infants of 25–35 weeks gestation were recruited after signed parental consent, and 0.5 ml blood samples for S-100 determination were taken at the same time as routine phlebotomy on days 1, 2, 3, 5, and 7 after birth. Routine cerebral ultrasound scans were undertaken during the stay on the unit. The study was approved by the Manchester research ethics committee (central).

S-100 protein was detectable in the serum of preterm infants and concentrations ranged from 0.85 to 22.0 µg/l (table 1).

Seven of the 30 infants had features of parenchymal damage on cranial ultrasound scan, with a median S-100 protein level of 3.39 µg/l. The remaining 23 infants had normal scans and had a median S100 protein level of 3.18 µg/l (table 2). The data were analysed using the Mann-Whitney U test, and no significant difference in levels of S100 protein was found between the two groups (p = 0.774).

Table 1 Serum S-100 protein levels in preterm infants with and without parenchymal damage as shown on cerebral ultrasound scanning

<table>
<thead>
<tr>
<th>Parenchymal damage</th>
<th>No damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>7</td>
</tr>
<tr>
<td>Median</td>
<td>3.39</td>
</tr>
<tr>
<td>Range</td>
<td>0.76–22.0</td>
</tr>
</tbody>
</table>

Table 2 Serum S-100 protein levels in preterm infants with and without parenchymal damage as shown on cerebral ultrasound scanning

<table>
<thead>
<tr>
<th>Serum S-100 protein (µg/l)</th>
<th>Day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Minimum</td>
<td>0.92</td>
</tr>
<tr>
<td>Maximum</td>
<td>13.3</td>
</tr>
</tbody>
</table>

<references>
5. Whitelaw et al.5 recently reported that S-100 protein concentration was 20–200 times higher than control levels in the cerebrospinal fluid of infants with posthaemorrhagic ventricular dilatation. S-100 protein is produced only within the brain by astrocytes, but it can be detected in the serum after cerebral damage in adults with stroke, where it is a marker of infarction volume,6 and it has also been found to be useful in head injury.7 A study of term infants found that serum S-100 protein levels were detectable after uncomplicated delivery.8 Cerebrospinal fluid is not often taken from preterm infants, and an easily obtainable serum marker for brain cell damage would be of considerable interest.

The aims of our study were to determine firstly whether S-100 protein could be measured in the serum of preterm infants during the first week after birth. Thirty preterm infants of 25–35 weeks gestation were recruited after signed parental consent, and 0.5 ml blood samples for S-100 determination were taken at the same time as routine phlebotomy on days 1, 2, 3, 5, and 7 after birth. Routine cerebral ultrasound scans were undertaken during the stay on the unit. The study was approved by the Manchester research ethics committee (central).

S-100 protein was detectable in the serum of preterm infants and concentrations ranged from 0.85 to 22.0 µg/l (table 1).

Seven of the 30 infants had features of parenchymal damage on cranial ultrasound scan, with a median S-100 protein level of 3.39 µg/l. The remaining 23 infants had normal scans and had a median S100 protein level of 3.18 µg/l (table 2). The data were analysed using the Mann-Whitney U test, and no significant difference in levels of S100 protein was found between the two groups (p = 0.774).

Table 1 Serum S-100 protein levels in preterm infants with and without parenchymal damage as shown on cerebral ultrasound scanning

<table>
<thead>
<tr>
<th>Parenchymal damage</th>
<th>No damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>7</td>
</tr>
<tr>
<td>Median</td>
<td>3.39</td>
</tr>
<tr>
<td>Range</td>
<td>0.76–22.0</td>
</tr>
</tbody>
</table>

Table 2 Serum S-100 protein levels in preterm infants with and without parenchymal damage as shown on cerebral ultrasound scanning

<table>
<thead>
<tr>
<th>Serum S-100 protein (µg/l)</th>
<th>Day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Minimum</td>
<td>0.92</td>
</tr>
<tr>
<td>Maximum</td>
<td>13.3</td>
</tr>
</tbody>
</table>
</references>
This study confirmed the presence of S-100 protein in the serum of preterm infants, but, in view of these findings, its measurement would not be useful as a marker of cerebral damage.

Acknowledgements: Cambridge Life Sciences performed the S-100 protein analyses.

T Chest, J McRobbie, J B Emmerson
Neonatal Medical Unit, St Mary's Hospital, Whitworth Park, Manchester M10 3JX, UK; anthony.emerson@man.ac.uk

References

Neonatal shaken baby syndrome—historical inexactitudes

I read with interest the article on neonatal shaken baby syndrome. Although a fascinating account of the sequence of events in this saga, it is factually incorrect in several respects. As the perinatal pathologist involved in the Birmingham series, I raised the possibility that the brain damage was due to the effects of physiotherapy prior to the publication of our report. My co-authors felt that the suggestion was too speculative to be included. It is, however, of note that the physiotherapy regime was changed at this time, as a precaution and as I remember I encountered only one further case until my retirement in 2000. At the time I presented the pathological data at several scientific meetings both in the UK and abroad, suggesting physiotherapy was relevant and also that the method used in Birmingham appeared to be unique in allowing free movement of the baby's head during treatment of the chest.

Some years later I received a telephone call from Dr David Becroft, the perinatal pathologist concerned with the New Zealand cases that pathologically appeared very similar to our own. They had no explanation for their cases at this time and I indicated that I had always been of the opinion that physiotherapy was responsible. As I understand it this resulted in changes in the physiotherapy regime in New Zealand and the disappearance of the lesions.

In retrospect, I should have insisted that my hypothesis, however speculative, was included in our original paper or expressed the view in the correspondence columns at the time because I might have prevented or at least reduced the number of affected cases in New Zealand. Certainly today I would not have been so reticent. In the event it is gratifying that detailed clinical analysis of the cases confirmed my original opinion.

As to the pathalogy of the condition, detailed unpublished studies of the affected brains in our series suggest the lesion is more akin to that of hydranencephaly than infantile shaken baby syndrome and leads me to raise the possibility that hydranencephaly may be the result of intra-uterine brain trauma.

D I Rushton
Retired Paediatric Pathologist
rushtonianoxon@aol.com

Neonatal shaken baby syndrome—lessons to be learned

Williams and Sunderland,1 and the accompanying commentary from Rosenbloom and Ryan,2 discuss a severe cystic brain lesion associated with chest physiotherapy in very preterm infants. Rosenbloom is correct that the topic lacks topicality, but mainly because neonatal chest physiotherapy is now used very little if at all. It is, however, of note that there is an abundant literature detailing appropriate treatment and the absence of brain damage associated with neonatal chest physiotherapy. Older data suggested benefit,3,4 but more recent publications demonstrate none.5 6 The reported benefits were transient improvements in oxygenation and slight increased removal of secretions. The older studies are all too small to adequately address safety. Chest physiotherapy, by whatever method, has little or no place in neonatal intensive care.

There are several lessons to be learned from the experience of the units who found these brain lesions. Firstly, a treatment generally recognised as being beneficial may not be so, especially with other changes in care over the passage of time. Continued reassessment of the usefulness of treatment is needed. Secondly, side effects can appear, even when a treatment has supposedly passed the test of time. Ongoing audit is needed. Thirdly, there is a dilemma that clinicians face in reporting complications. The first hospital to find this lesion did not further investigate the cause, report its suspicions, or inform the parents of the affected babies.7 The second hospital did all of these.8 That hospital has been subject to a long official public inquiry and law suites, and had 20 medical and physiotherapy staff investigated by registration authorities, lasting 8 years. All this happened in the supposedly non-litigious medicolegal environment of New Zealand. There needs to be the ability to be open about complications and side effects and have an atmosphere of learning from, rather than blame for, them.

I would like to correct one statement by Williams and Sunderland. In our nursery, there was no change in the vigour of chest physiotherapy from the introduction of the technique in 1985 until we stopped all chest physiotherapy at the end of 1994. The cerebral lesions appeared 1992–94. From 1985, the same physiotherapist was teaching and supervising the technique. During those 3 years, babies who developed the brain lesion had more chest physiotherapy than matched controls, but considerably less than many infants in previous years. Why the brain lesion began to appear remains a mystery.

D B Knight
Neonatal Paediatrician
National Women's Hospital, Auckland, New Zealand
david@adhb.govt.nz

References

Authors’ reply

We are grateful to colleagues for their comments on our annotation. We would stress that we merely abstracted the views of others, so any criticisms (apart from our brevity) will be of the lawyers, doctors, nurses, physiotherapists, and parents who contributed to the Royal Commission Report. We found it to be systematic, rational, and objective.

We strongly refute any suggestion that any of the New Zealand professionals should be criticised let alone made scapegoats (witness our final paragraph). We are puzzled that Drs Rosenbloom and Ryan discount the quoted witness statements of the parents and involved clinicians. The lawyers and doctors are clear that the physiotherapy and nursing practices did occur and that the levels of head shaking were not monitored. We are concerned with infant brain injuries not lung disease and consider this to be topical. We share colleagues’ concern at the need to base opinions on speculative presumption extrapolated from animal or accident research and are aware of the limited evidence that identifies the minimal forces needed to cause shaken brain damage in neonates or older infants. We found the reported experiences to be a helpful insight.

We are delighted that Dr Rushton has taken this opportunity to state he thought vigorous chest physiotherapy without supporting the head was responsible for the porencephalic lesions and to inform of his possible involvement in advising New Zealand colleagues. We understand there were earlier concerns that publishing the speculation about physiotherapy would open liability to litigation. Lawyers might consider the inference that

www.archdischild.com
fear of litigation led to suppression of information that might have prevented the New Zealand deaths and the dilemma facing clinicians who reported the cerebral implications of vigorous physiotherapy. Dr Knight reports their unit has been 'subject to a long official inquiry, law suits and had 20 medical, nursing, and physiotherapy staff investigated by registration authorities, lasting 8 years.'

We do not accept criticisms of inaccurate references. The literature review we both cited was last updated in 1997. There has been an updated review this year (dealing with lung not brain disease), which was unavailable to the editors or us at the time of submission. Dr Knight states 'there was no change in the vigour of chest physiotherapy from 1985 until the end of 1994 but he co-authored the paper' we cited that states that there was no policy to support the head during chest physiotherapy and no data on the extent the head moved during physiotherapy, whether given by nurses or physiotherapists. The Royal Commission Report found no record of the vigour of chest percussion and understood there was considerable variation with no standardisation of training.

We recommend interested colleagues to read this report and the publications of Knight et al 1 before dismissing the possibility that vigorous chest physiotherapy without supporting the head may cause brain injuries in certain circumstances.

R Sunderland
Birmingham Children’s Hospital; rs.sunderland@bch.nhs.uk

A N Williams
Northampton General Hospital; anw@doctors.org.uk

References

SIDS, smoking, and arousal thresholds: conclusions not supported by data

The investigation of the effect of maternal tobacco smoking on arousal in healthy infants1 concluded that maternal tobacco smoking increases arousal thresholds (i.e. impairing arousal) in infants of 2–3 months of age, during quiet sleep in the supine position. It is suggested that this may provide an explanation for the association between smoking and sudden infant death syndrome (SIDS).

This conclusion is not supported by the data because the study also found that maternal tobacco smoking reduces arousal thresholds in 2–3 month old infants, in active sleep in the prone position—the very position in which victims of SIDS are still most commonly found.2–3 Could passive smoking then be protective of death from SIDS?

Smoking is undoubtedly associated with SIDS. However, these contradictory findings do not support the hypothesis that an alteration of infants’ arousal thresholds by passive smoking is etiological.4 Is it not time that SIDS research concentrated less on smoking and more on alternative mechanisms?

R S C Horne
Senior Research Fellow
Monash University
rosemary.horne@med.monash.edu.au

References
1 Blyth T, McKenzie S. SIDS, smoking and arousal thresholds: conclusions not supported by data [electronic response to Horne RSC et al. Effects of maternal tobacco smoking, sleeping position, and sleep state on arousal in healthy term infants. Arch Dis Child Fetal Neonatal Ed 2002;87:F100–5].

Swallowing induced supraventricular tachycardia in a neonate

We would like to report on an infant with swallowing induced supraventricular tachycardia (SVT). This has rarely been described in adults, but, to our knowledge, has not been previously reported in neonates or children.

A male infant weighing 4500 g was born by vaginal delivery at term after a normal pregnancy. He was admitted to the neonatal unit for phototherapy and was diagnosed with SVT. There was no haemodynamic instability and he was cardioverted with adenosine. He had recurrent SVT and was started on antiarrhythmic treatment. He subsequently had recurrent SVT which was not to be precipitated by feeding. SVT did not appear to be triggered by sucking a pacifier but occurred within seconds of feeding. Termination of the SVT usually occurred spontaneously about 30 minutes after the end of a feed. On a few occasions, longer periods of SVT required adenosine for cardioversion. In an attempt to control his SVT, oral feeds were discontinued and he was started on intravenous fluids. He remained in sinus rhythm throughout 18 hours of fasting. When feeding was resumed, he again developed SVT. Treatment with digoxin or propranolol at therapeutic levels did not control the SVT.

There was no evidence of Wolff-Parkinson-White syndrome on the electrocardiogram, which showed a normal cardiac anatomy with good ventricular function. A barium swallow was performed, which revealed a normal oesophageal anatomy and swallowing mechanism. An abdominal ultrasound was normal and showed good diaphragmatic movement with respiration.

Treatment with increasing doses of flecainide resulted in a reduction in the frequency and duration of the SVT. Before discharge on flecainide 3.5 mg/kg/day, a 24 hour continuous ECG recording did not produce any evidence of SVT. This patient subsequently had recurrent SVT unassociated with swallowing and remains on antiarrhythmic treatment.

Swallowing induced SVT has been recognised in adults without evidence of gastro-oesophageal disease5 and in association with pharyngolplastic manipulations.6 In one intractable case, intraluminal repositioning of the oesophagus to physically separate it from the right atrium successfully achieved control.7 Swallowing increases vagal tone, and thus termination of SVT is often associated with swallowing and other vagal...
management. Changes in vasoconstrictive tone or perhaps mechanical stimulation are possible causes for this unusual phenomenon.

M Ni Chroinin, P Oslizlok, A Saidi
Our Lady’s Hospital for Sick Children, Dublin, Ireland
Correspondence to: Dr Ni Chroinin, 33 Fremont Drive, Melbourn, Bishopspong, Cork, Ireland; michroinin@yahoo.com

Management of mothers of neonates with vertically transmitted sexually transmitted infections

Vertical transmission of sexually transmitted infections such as *Chlamydia trachomatis* and *Neisseria gonorrhoeae* can cause ophthalmia neonatorum and rarely pulmonary infection.1 To optimise the management of mothers, and their partners, of neonates diagnosed with these infections, we set up a system of direct fax referrals between our Microbiology Department and the local genital-urinary medicine (GUM) clinic. This is in line with the national strategy for sexual health,2 which stresses greater collaboration between agencies. A similar direct referral system is already in place for gynaecology agencies. A similar direct referral system for sexual health and HIV. London: Department of Health, 2001.


Dobie, J Gray
Department of Microbiology, Birmingham Children’s Hospital, Birmingham B4 6NH, UK

M Huangberg
GU Medicine, Whitall Street Clinic, Birmingham B4 6DH, UK

K Berry
Accident & Emergency Department, Birmingham Children’s Hospital, Birmingham B4 6NH, UK

M Hocking
Neonatal Unit, Birmingham Women’s Hospital, Birmingham B15 2TG, UK

References


Decreasing oxygen saturation in very early preterm newborn infants after transfusion

Very early preterm infants are born at a time when more than 90% of their red blood cells contain fetal haemoglobin (HbF) and therefore their blood has a high affinity for oxygen. Because of blood sampling, early preterm newborns often receive transfusions for blood volume replacement. These transfusions are carried out with adult red blood cells containing adult haemoglobin (HbA) and decrease the HbO2 affinity.

The change in PaO2 after transfusion has not previously been published in human preterm infants. A study was therefore planned to be carried out during the first week of life in very early preterm infants to determine the decrease in HbO2 affinity (Po2 required to achieve a saturation of 50% at pH 7.4 and 37°C) after a single transfusion as well as the relation of PaO2 to the saturation of the HbO2.

The posttransfusion infants of about 26 weeks gestation, free of any congenital anomalies and transfused during the first week of life, were included in the study. The oxygen dissociation curve and the PaO2 were determined by Hemox-Analyser (TCS Scientific Corp, New Hope, Pennsylvania, USA) as previously described. A 30 μl volume of whole blood was added to 4 ml buffer (135 mM NaCl, 30 mM TES, 5 mM KCl and NaOH adjusted to pH 7.4 ± 0.02; TCS buffer; TCS Scientific Corp), 10 μl antifoam solution, and 20 μl 20% bovine serum albumin. Samples were analysed immediately on collection from the patient. Nitrogen (100%) was bubbled through the sample at a constant rate that resulted in complete deoxygenation within 20 minutes, followed by reoxygenation with air for 15 minutes. The analyser measured the oxygen tension with a standard Clark oxygen electrode (model 5331 Oxygen Probe; Yellow Springs Instrument Co, Yellow Springs, Ohio, USA).

The mean (SD) gestational age was 23.3 (1) weeks and the mean (SD) birth weight was 755 (185) g. The mean (SD) volume of red blood cells transfused (packed cell volume 0.5%) was 21.3 (6) ml (28.47 ml/kg). Haemoglobin levels before and after transfusion were 98 (9) and 134 (10) g/l respectively. The percentage of HbF was 92.9 (1.2) before and 43.3 (5.8), 2.8 (1) days after a transfusion. The value for PaO2 increased from 18.1 (1.0) to 21.0 (1.1) mm Hg (P = 0.007). The PaO2, if known after a transfusion, could be useful to predict the range of adequate saturation.

This work was supported by Canadian Institutes of Health Research grant no MOP 49464.

V De Halieux, C Gagnon, H Bard
Division of Neonatology, Department of Pediatrics, University of Montreal, St Justine Hospital and Research Center, 3175, Côte-Sainte-Catherine, Montreal, Quebec H3T 1C5, Canada; harry.bard@umontreal.ca

References


R Nicholl, K Nistala
Northwick Park Hospital
kiran@nistala.freerose.co.uk

References


www.archdischild.com
BOOK REVIEW

The Lazarus case, life and death issues in neonatal intensive care

When things go badly wrong in the perinatal period there has developed a culture in many “advanced societies” that demands a search for someone to blame. This search for guilt, accountability, punishment, and recompense often results in litigation.

In this thought provoking book John D Lantos describes such lawsuits as “our public morality plays” and uses his experience as a neonatologist, expert witness, and ethicist to create, debate, and crystallise relevant issues of ethics related to the neonatal intensive care of a fictional preterm infant who should have died but did not—The Lazarus Case.

A fictitious neonatologist, Dr Miller, decides to stop resuscitation of a very preterm infant who seems past reasonable care. The baby who might have died survived with severe neurological problems and the parents sue Dr Miller, alleging that stopping treatment was negligent. John Lantos places himself in the role of expert witness and uses questions put by the plaintiff’s lawyers to explore the moral, ethical, legal, and social factors and to illustrate the ambiguities, misunderstandings, responsibilities, and evasions highlighted by the perinatal care of a 25 week gestation infant.

A key question put to Dr Lantos by one lawyer was “Can studying philosophy tell you whether a doctor does in a particular case is right or wrong?” Probably not is the final conclusion reached by Dr Lantos, but it was just as unlikely that definitive guidance would come from sociology, religious doctrine, strict medical protocols, or any other single source.

There have been many attempts over the past half century to face and explain the moral dilemmas associated with our attempts to save the lives, prevent damage, and encourage optimal development of critically ill preterm infants. The Lazarus Case reviews in a most effective, compelling, erudite, and compassionate way the enormous complexity of these issues. It is highly recommended to all who are concerned with the care of preterm infants and their families and is essential reading for those required to provide medicolegal advice on life and death issues in neonatal intensive care.

Forrester Cockburn

CD REVIEW

Echocardiography for the neonatologist. Part 2. Structural and transitional haemodynamic problems in the newborn. Practical
N Evans, G Malcolm. Royal Albert Hospital, Sydney.

This second CD, covering structural and transitional haemodynamic problems in the newborn, is the companion volume to part 1, which dealt with normal 2D imaging and Doppler. In this latest volume, the authors deal comprehensively with the use of echocardiography in the diagnosis and assessment of preterm patent ductus arteriosus, pulmonary hypertension, and low output states. They also provide an introduction to recognition of structural cardiovascular malformations.

The CD is divided into six sections that deal, respectively, with the ductus arteriosus, atrial shunting, measurement of flow and ventricular output, assessment of ventricular function and hypertrophy, measurement of pulmonary artery pressure, and an introductory description of common types of cardiovascular malformation. Images are mainly provided as a mixture of text and video clips.

The first section on patent ductus arteriosus is excellent, providing many examples of the diagnosis and assessment of functional importance. The section on measurement of pulmonary artery pressure provides a valuable insight into one of the more important applications of cardiac ultrasound in neonatology. The sections on atrial shunting, flow measurement, and assessment of ventricular function cover applications of cardiac ultrasound that are likely to be less familiar to most neonatologists and will require more assimilation. The final section, on structural congenital heart disease, is really only an introduction to what is obviously a very large subject. The authors stress that suspicion or confirmation of a cardiovascular malformation should lead directly to a cardiological referral and they highlight the difficulty in exclusion or confirmation of some diagnoses, particularly total anomalous pulmonary venous connection and coarctation of the aorta. Some of the examples of cardiovascular malformations are of rather disappointing quality and some of the more difficult problems, such as coarctation of the aorta, are dealt with only very briefly. There is also possible confusion between coarctation of the aorta and interruption, which cardiologists regard as different abnormalities. The self assessment section offers the opportunity of testing your skills in recognition of various examples but there is no leeway in terminology. For example, TAPVC (connection) is counted as a wrong answer for TAPVD (total anomalous pulmonary venous “drainage”).

Overall this is a valuable guide to the way in which neonatologists should use echocardiography and what they should expect to be able to achieve. I think it is likely to be of more use than a textbook as echocardiography is mainly about interpretation of moving images. Details of both CDs are available at www.cs.nsw.au/trpa/neonatal/default.htm.

C Wren